-- Days : -- HRS : -- MIN : -- SEC

Register Now →

Subscribe

News
Video
Podcasts
Journals
Conferences
Events
Resources
CE
About AJMC
Subscribe

Spotlight -

Free In-Person Regional Events Focused on Oncology and Population Health

Opinion|Videos|March 21, 2025

Integrating Bispecific Antibodies in Community Oncology: Benefits and Considerations

Experts discuss the benefits of implementing and operationalizing bispecifics in the community oncology setting.

Episodes in this series

EP. 1 Expanding Horizons: The Present and Future of Bispecific Antibodies Across Oncology

EP. 1 Expanding Horizons: The Present and Future of Bispecific Antibodies Across Oncology

3 experts are featured in this series.

EP. 2 Revolutionizing Cancer Treatment: Key Bispecific Antibody Approvals

3 experts are featured in this series.

EP. 3 How Bispecific Antibodies Are Reshaping Cancer Care

3 experts are featured in this series.

EP. 4 Optimizing Bispecific Antibody Use: Opportunities to Broaden Patient Access

3 experts are featured in this series.

EP. 5 Integrating Bispecific Antibodies in Community Oncology: Benefits and Considerations

3 experts are featured in this series.

EP. 6 Overcoming Key Operational Challenges in Integrating Bispecific Therapies

3 experts are featured in this series.

EP. 7 Partnerships in Bispecific Therapy: A Model for Supporting Community Oncology

3 experts are featured in this series.

EP. 8 Managing Complexity: Standardizing Workflows for Multiple Bispecific Therapies

3 experts are featured in this series.

EP. 9 Standardizing CRS Management and Ensuring Smooth Transitions of Care in Bispecific Therapy

3 experts are featured in this series.

EP. 10 Optimizing Bispecific Antibody Administration With EHR and Technology Solutions

3 experts are featured in this series.

EP. 11 Addressing Resource and Bandwidth Challenges in Bispecific Antibody Administration

3 experts are featured in this series.

EP. 12 Payer and Reimbursement Considerations for Bispecific Therapies

3 experts are featured in this series.

EP. 13 Emerging Therapeutic Areas for Bispecific Antibodies

3 experts are featured in this series.

EP. 14 Incorporating Bispecific Antibodies Earlier in Treatment and Improving Access in Underserved Communities

3 experts are featured in this series.

EP. 15 Future Breakthroughs: What’s Next for Bispecific Antibodies in Oncology?

Video content above is prompted by the following:

What are the benefits of implementing/operationalizing bispecifics in the community oncology setting?

Newsletter

Stay ahead of policy, cost, and value—subscribe to AJMC for expert insights at the intersection of clinical care and health economics.

Related Content

Access and Adherence: Navigating Insurance Coverage and Real-World Barriers to Biomarker Testing in Extrapulmonary Neuroendocrine Carcinoma

ByRyan Haumschild, PharmD, MBA,William K. Oh, MD,Aman Chauhan, MD,Namrata Vijayvergia, MD,Sandy Kotiah, MD

July 6th 2026

Tracking Progress and Bridging Guideline Gaps in Atopic Dermatitis Care

ByAngela J. Lamb, MD

July 6th 2026

Clinical Pathways, Barriers, and Infrastructure Needs in Biomarker Testing for Extrapulmonary Neuroendocrine Carcinoma

ByRyan Haumschild, PharmD, MBA,William K. Oh, MD,Aman Chauhan, MD,Namrata Vijayvergia, MD,Sandy Kotiah, MD

July 6th 2026

Jack Mosey of emtelligent discussed how the company's core product can promote EHR-to-EDC, a key labor saving step in clinical trials. | Image: LinkedIn

emtelligent Turns Unstructured Clinical Data Into Actionable Insights

July 5th 2026

Dr Rahul Banerjee | Image Credit: Fred Hutch Cancer Center

Tec-Dara Shows MRD-Negative, PFS Benefit in High-Risk Myeloma, But Longer Follow-Up Needed: Rahul Banerjee, MD

ByBrooke McCormick,Rahul Banerjee, MD

July 4th 2026

Trending on AJMC

emtelligent Turns Unstructured Clinical Data Into Actionable Insights

Early Treatment Succeeds in CRC With Next-Generation KRAS Inhibitor Calderasib Plus Cetuximab Combo

Tec-Dara Shows MRD-Negative, PFS Benefit in High-Risk Myeloma, But Longer Follow-Up Needed: Rahul Banerjee, MD

Adam Kittai, MD, on Sequencing, Cost, and the Road to CLL Cure

Real-World Data Show MASH Progresses Faster Than Trials Suggest